Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?

Endocrine

Volumn 53, Issue 1, 2016, Pages 58-62

  Grillo, Federica ^a,b   Albertelli, Manuela ^a   Annunziata, Francesca ^a   Boschetti, Mara ^a,b   Caff, Andrea ^a,c   Pigozzi, Simona ^a,b   Ferone, Diego ^a,b   Mastracci, Luca ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Classification; Grade; Ki 67; Neuroendocrine tumors

Indexed keywords

KI 67 ANTIGEN;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORPHOLOGY; FEMALE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL ANALYSIS; WORLD HEALTH ORGANIZATION; CLASSIFICATION; INTESTINE TUMOR; MORTALITY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; STOMACH TUMOR; SURVIVAL RATE;

HUMANS; INTESTINAL NEOPLASMS; KI-67 ANTIGEN; NEOPLASM GRADING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84941333411     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0734-3     Document Type: Article

References (18)

1. B.I. Gustafsson, M. Kidd, I.M. Modlin, Neuroendocrine tumors of the diffuse neuroendocrine system. Curr. Opin. Oncol. 20, 1–12 (2008)
2. I.M. Modlin, K. Oberg, D.C. Chung, R.T. Jensen, W.W. de Herder, R.V. Thakker, M. Caplin, G. Delle Fave, G.A. Kaltsas, E.P. Krenning, S.F. Moss, O. Nilsson, G. Rindi, R. Salazar, P. Ruszniewski, A. Sundin, Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61–72 (2008)
3. C. Capella, E. Solcia, L.H. Sobin, in Pathology and genetics of tumours of the digestive system, ed. by S.R. Hamilton, L.A. Aaltonen (IARC Press, Lyon, 2000), pp. 77–82
4. G. Rindi, G. Klöppel, H. Alhman, M. Caplin, A. Couvelard, W.W. de Herder, B. Erikssson, A. Falchetti, M. Falconi, P. Komminoth, M. Körner, J.M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J.Y. Scoazec, B. Wiedenmann, all other Frascati Consensus Conference participants, European Neuroendocrine Tumor Society (ENETS), TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449, 395–401 (2006)
5. G. Rindi, G. Klöppel, A. Couvelard, P. Komminoth, M. Körner, J.M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J.Y. Scoazec, B. Wiedenmann, TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 451, 757–762 (2007)
6. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (eds.), WHO classification of tumours of the digestive system (IARC Press, Lyon, 2010), pp. 13–14
7. L. Sobin, M. Gospodarowicz, C. Wittekind (eds.), UICC/AJCC TNM classification of malignant tumours, 7th edn. (Wiley, New York, 2009)
8. U.F. Pape, H. Jann, J. Mueller-Nordhorn, A. Bockelbrink, U. Berndt, S.N. Willich, M. Koch, C. Röcken, G. Rindi, B. Wiedenmann, Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113, 256–265 (2008)
9. H. Jann, S. Roll, A. Couvelard, O. Hentic, M. Pavel, J. Mueller-Nordhorn, M. Koch, C. Roecken, G. Rindi, P. Ruszniewski, B. Wiedenmann, U.F. Pape, Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117, 3332–3341 (2011)
10. J. Strosberg, A. Nasir, D. Coppola, M. Wick, L. Kvols, Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Human Pathol. 40, 1262–1268 (2009)
11. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, Cutsem E. Van, T.J. Hobday, T. Okusaka, J. Capdevila, E.G. de Vries, P. Tomassetti, M.E. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Lebwohl, K. Öberg, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group, Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 10(364), 514–523 (2011)
12. F. Grillo, S. Pigozzi, P. Ceriolo, P. Calamaro, R. Fiocca, L. Mastracci, Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections. Histochem. Cell Biol. 144(1), 93–99 (2015)
13. V. Adsay, Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. Am. J. Surg. Pathol. 36, 1743–1746 (2012)
14. M.D. Reid, P. Bagci, N. Ohike, B. Saka, I. Erbarut Seven, N. Dursun, S. Balci, H. Gucer, K.T. Jang, T. Tajiri, O. Basturk, S.Y. Kong, M. Goodman, G. Akkas, V. Adsay, Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Modern Pathol. 28, 686–694 (2015)
15. O. Basturk, Z. Yang, L.H. Tang, R.H. Hruban, V. Adsay, C.M. McCall, A.M. Krasinskas, K.T. Jang, W.L. Frankel, S. Balci, C. Sigel, D.S. Klimstra, The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am. J. Surg. Pathol. 39, 683–690 (2015)
16. E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.S. Chen, D. Hörsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S. Patyna, D.R. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 10(364), 501–513 (2011)
17. J.R. Strosberg, R.L. Fine, J. Choi, A. Nasir, D. Coppola, D.T. Chen, J. Helm, L. Kvols, First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 15(117), 268–275 (2011)
18. K. Öberg, U. Knigge, D. Kwekkeboom, A. Perren, ESMO Guidelines Working Group, Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 Suppl 7, vii124–vii130 (2012)